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ABSTRACT 
Background 
The heterogeneity of metastatic breast cancer (MBC) necessitates novel biomarkers 
allowing stratification of patients for treatment selection and drug development. We 
propose to use the prognostic utility of circulating tumor cells (CTCs) for stratification of 
patients with stage IV disease.   
Methods 
In a retrospective, pooled analysis of individual patient data from 18 cohorts, including 
2,436 MBC patients, a CTC threshold of 5 cells per 7.5 ml was used for stratification 
based on molecular subtypes, disease location, and prior treatments. Patients with ≥ 5 
CTCs were classified as Stage IVaggressive, those with < 5 CTCs as Stage IVindolent. 
Survival was analyzed using Kaplan-Meier curves and the log rank test.  
Results 
For all patients, Stage IVindolent patients had longer median overall survival than those 
with Stage IVaggressive (36.3 months vs. 16.0 months, P<0.0001) and similarly for de novo 
MBC patients (41.4 months Stage IVindolent vs. 18.7 months Stage IVaggressive, p<0.0001). 
Moreover, patients with Stage IVindolent disease had significantly longer overall survival 
across all disease subtypes compared to the aggressive cohort: hormone receptor-
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positive (44 months vs. 17.3 months, P<0.0001), HER2-positive (36.7 months vs. 20.4 
months, P<0.0001), and triple negative (23.8 months vs. 9.0 months, P<0.0001). Similar 
results were obtained regardless of prior treatment or disease location.   
Conclusions 
We confirm the identification of two subgroups of MBC, Stage IVindolent and Stage 
IVaggressive, independent of clinical and molecular variables. Thus, CTC count should be 
considered an important tool for staging of advanced disease and for disease 
stratification in prospective clinical trials. 
Keywords: circulating tumor cells, CTCs, metastatic breast cancer, MBC, biomarker, 
survival 
 
 
INTRODUCTION 
Metastatic breast cancer (MBC) can occur with de novo presentation or upon the 
development of recurrent disease after completion of primary (local) treatment.1 Once 
diagnosed by physical exam, radiological tests, and pathology, current treatment of this 
condition is palliative. In spite of the increasing availability of targeted and systemic 
therapies, approximately 41,000 women in the United States and over half a million 
worldwide die of MBC annually.2,3 In order to better assess survival benefit from novel 
potential treatments in prospective, randomized clinical trials, there is a critical need of 
new tools for prognostic stratification, particularly with regards to endocrine therapies.4,5  
The detection of circulating tumor cells (CTCs) is prognostic during the course of 
the disease in women with MBC.6 Several prospective studies, including a large pooled 
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analysis, confirmed the prognostic value of baseline CTC detection in both first-line and 
refractory MBC.7,8 The prognostic value of CTC detection and enumeration stimulated a 
number of molecular studies aimed at evaluating the biological features of CTCs. These 
studies demonstrated the fundamental role of these cells in the metastatic process and 
suggested potential therapeutic approaches.9-12 A single, prospective, randomized study 
was designed to evaluate the clinical utility of CTC enumeration by testing the 
hypothesis that an early change of chemotherapy regimen could modify outcome of 
patients with a baseline level of ≥5 CTCs per 7.5 mL of blood.13 This study failed to 
demonstrate the validity of this therapeutic approach, but it confirmed that patients with 
elevated CTC count at baseline had worse outcomes not affected by current standard 
therapies when compared to patients with <5 CTCs.13  
The American Joint Committee on Cancer (AJCC) TNM staging classification 
provides an assessment of disease burden based on anatomical location and disease 
characteristics to define prognosis.14 In the last revisions of the staging system, the use 
of novel diagnostic tests has been included.14 Nevertheless, Stage IV breast cancer, or 
MBC, continues to be considered a uniform disease in spite of known variability in 
clinical outcomes in patients with different disease subtypes and sites of metastasis. We 
postulated that CTC enumeration could be used to stratify patients with MBC, 
irrespective of disease subtype, line of therapy, and site of disease. Here, by 
retrospective analysis of individual patient data from 18 cohorts, including 2,436 patients 
with MBC, we demonstrated that CTC enumeration should be used to evaluate 
prognosis and expect that CTC-based staging will impact the development for new 
treatments of MBC. 
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 METHODS  
We performed a large, retrospective pooled analysis of individual patient data to 
demonstrate that CTC enumeration could effectively stratify MBC into two distinct 
subgroups, indolent (Stage IVindolent) and aggressive (Stage IVaggressive), with defined 
outcome. This analysis included patients from the 17 European Centers participating in 
the European Pooled Analysis Consortium (EPAC) and a single large U.S. institution, 
the MD Anderson Cancer Center (MDACC).7 Centers are listed in Supplemental Table 
1. The anonymized data were transferred to the Robert H. Lurie Comprehensive Cancer 
Center-Bioinformatics Core Facility. A retrospective Institutional Review Board-
approved protocol was used to access and analyze the data. For all participants, CTC 
enumeration was performed using the CellSearch™ method (Menarini Silicon 
Biosystems, LLC), which is approved by the Food and Drug Administration (FDA), to 
evaluate whole blood specimens collected before initiation of a new treatment.  
Estrogen receptor, progesterone receptor, and HER2 status were performed at 
each participating institution following standard procedures and guidelines, and patients 
were treated with endocrine therapy, chemotherapy, HER2-targeted therapy, or a 
combination as appropriate. Standard imaging studies were used for baseline staging 
and response assessment. Disease in patients with fewer than 5 CTCs per 7.5 mL of 
blood was classified as Stage IVindolent. Disease in those with 5 or more CTCs per 7.5 
mL of blood was classified as Stage IVaggressive. The study diagram is shown in 
Supplemental Figure 1.   
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Statistical Analysis 
Patient characteristics were summarized through descriptive analysis and 
differences between datasets were tested through Pearson's chi-square test. 
Continuous variables were reported through median and range, whereas categorical 
variables were described through frequency distribution. 
Survival analyses were performed in each cohort separately, and then the 
cohorts were combined. Overall survival was defined as the time from baseline CTC 
enumeration to death from any cause or date of last follow-up. Progression-free survival 
was defined as the time from baseline CTC enumeration to disease progression 
(according to RECIST criteria) or death from any cause or date of last follow-up. 
Censoring was applied to patients without an endpoint event at the last follow-up visit. 
Hazard ratios (HR) and confidence intervals (CI) were reported. A P value of less than 
0.05 was considered to indicate statistical significance. Survival was analyzed by log-
rank test and represented by Kaplan-Meier estimator plot. Cumulative Hazard function 
was represented through Nelson–Aalen estimator. Patient subgroups were compared 
using multivariate analyses based on the Cox proportional-hazards method. HR and 
their P-values were calculated using Cox regression. Statistical analysis was performed 
using SAS software, Version 9.4 (SAS Institute Inc. (2014) Cary, NC) and STATA, 
Version 14.2 (StataCorp LP. (2015) College Station, TX).    
 
 
RESULTS 
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Individual Analysis 
The EPAC cohort consisted of individual patient data of MBC patients with 
baseline CTCs collected prior to initiation of a new treatment. Data were collected from 
17 centers in Europe from 2003 to 2012. The EPAC cohort included 1,944 patients. The 
details for how this cohort was obtained were published previously.7 A CTC cutoff of 5 
CTCs per 7.5 mL was selected based on prior studies.6 A total of 1,033 (53.1%) 
patients had Stage IVindolent disease, defined as < 5 CTCs per 7.5 mL of blood, and 911 
patients (46.9%) had baseline CTCs of ≥ 5 (Stage IVaggressive disease). Median CTC 
count was 3 per 7.5 mL (range 0-58,160). The second cohort consisted of individual 
patient data from 492 patients treated at the MDACC from 2002 to 2009. The MDACC 
cohort had a total of 303 (61.6%) patients with Stage IVindolent disease and 189 patients 
(38.4%) with Stage IVaggressive disease. Median CTC count was 2 per 7.5 mL (range 0-
1,780).  
First, each cohort was analyzed individually using Cox regression analyses. In 
the EPAC cohort, the Stage IVaggressive group had significantly shorter progression-free 
survival (HR 1.91, 95% CI 1.72-2.12, 12.4 months vs. 23.6 months, p<0.0001) and OS 
(HR 2.68, 95% CI 2.35-3.06, 15.4 months vs. 37.1 months, P<0.0001), compared with 
the Stage IVindolent group. Similarly, in the MDACC cohort, the Stage IVaggressive group 
was associated with significantly shorter progression-free survival (HR 1.50, 95% CI 
1.24-1.82, 5.94 months vs. 6.64 months, P<0.007) and overall survival (HR 2.43, 95% 
CI 1.45-2.29, 19.1 months vs. 31.3 months, P<0.0001) compared with the Stage IVindolent 
group (Supplemental Figure 2). 
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Combined Analysis 
Data from 2,436 patients were included in the combined analysis including 533 
patients with de novo stage IV disease (Table 1). The median age for the combined 
cohort was 57 years (range 27-91), and the median follow-up was 14.9 months (0.1-
90.1). At the time of last follow-up, 1,878 patients (77%) had progressed and 1,221 
(50%) had died of MBC. Seventy-four percent (1,755 patients) were estrogen receptor 
positive, 24% (571 patients) were HER2 positive, and 15% (358 patients) had triple-
negative breast cancer.  
At baseline, approximately 46% of patients had not received systemic therapy in 
the advanced setting including 533 patients with de novo disease. Approximately 20% 
of patients had been treated with one prior line of therapy, and 34% of patients had 
been treated with two or more lines of therapy at the time of baseline CTC collection. In 
terms of sites of metastasis, 68% had visceral metastasis, 66% had bone metastasis, 
and 43% had both visceral and bone metastases. After CTC collection, approximately 
44% of patients were treated with chemotherapy, 37% received chemotherapy 
combined with a biologic or targeted therapy, 13% had endocrine monotherapy, and the 
remaining 6% were classified as other.    
There was a statistically significant difference in OS (36.3 months vs. 16.0 
months, P<0.0001, log-rank) in favor of patients with Stage IVindolent disease, compared 
to those with Stage IVaggressive disease (Figure 1A). Moreover, CTC enumeration was 
also able to stratify patients with de novo Stage IV disease. Median OS of patients with 
de novo Stage IVindolent disease compared to that of the de novo Stage IVaggressive 
patients was 41.4 months versus 18.7 months (P<0.0001, log-rank) (Figure 1B). The 
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indolent cohort had better OS irrespective of the location of disease. Stage IVindolent 
patients with visceral disease had a median overall survival of 29.9 months compared to 
13.2 months for the Stage IVaggressive group (p<0.0001 by log rank test) (Figure 1C). 
Similarly, the median OS in patients with bone-only disease was 46.9 months compared 
to 23.8 months (p<0.0001 by log rank test) (Figure 1D), confirming the significant 
prognostic difference between the two stage IV subgroups defined by CTC frequency. 
 
CTCs, lines of therapy, and disease subtype 
Patients with MBC are treated with a sequence of systemic therapies selected 
following evaluation of standard biomarkers, such as hormone receptors and HER-2 
status. Endocrine therapy is the standard of care for patients with hormone receptor-
positive disease, HER2-targeted biological therapies are used primarily in combination 
with chemotherapy. Triple-negative breast cancer patients are primarily treated with 
cytotoxic chemotherapy, frequently combinations regimens. The probability of response 
and the ability to control disease progression decreases when patients receive multiple 
lines of treatment. Patients that failed first-line therapy had CTCs positivity that varies in 
disease subtypes, approximately 52% in hormone-receptor positive disease and 33% 
and 37% respectively for HER2 positive and triple negative breast cancers. Analysis of 
the combined cohort demonstrated that patients with untreated recurrent Stage IVindolent 
had a median OS of 44.6 months compared to only 22.8 months in patients with Stage 
IVaggressive disease (p<0.0001, log-rank) (Supplemental Figure 3). In patients with 
refractory disease who had received more than one line of systemic therapy, CTCs 
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discriminated the two prognostic groups (27.3 months vs. 12.0 months, respectively, 
p<0.0001, log-rank).  
The combined cohort was then stratified based on disease subtypes. The Stage 
IVindolent cohort had significantly longer overall survival across all disease subtypes 
compared to the aggressive cohort. Specifically, for patients with hormone receptor-
positive disease, overall survival was significantly longer for patients with Stage IVindolent 
compared to Stage IVaggressive disease (40.7 months vs. 17.3 months, P<0.0001, log-
rank). Stage IVindolent also had longer overall survival for triple-negative breast cancer 
(23.8 months vs. 9.1 months, P<0.0001, log-rank) and HER2-positive subgroups (33.2 
months vs. 19.4 months, P<0.0001, log-rank) (Figure 1E-G). Cumulative hazard ratio 
for Stage IVindolent and Stage IVaggressive classification by breast cancer subtype 
distinguished a particularly aggressive triple-negative breast cancer cohort (Figure 2A-
B).  
CTC enumeration was also able to stratify survival for both untreated patients 
and patients with prior lines of treatment, across subtypes for Stage IVindolent versus 
Stage IVaggressive with hormone receptor-positive (untreated: 51.1 months vs. 26.4 
months, P<0.0001; prior treatment: 30.2 months vs. 12.8 months, P<0.0001, log-rank), 
triple negative (untreated: 36.3 months vs. 9.1 months, P<0.0001; prior treatment: 15.9 
months vs. 9.0 months, P<0.0001, log-rank), and HER2-positive disease (untreated: 
55.4 months vs. 29.7 months, P<0.0001; prior treatment: 29.2 months vs. 13.3 months, 
P<0.0001, log-rank) (Supplemental Figure 4). In the refractory setting, the Stage 
IVindolent group performed consistently better within each disease subtype compared to 
the Stage IVaggressive group. For the total cohort, a significant survival difference between 
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Stage IVindolent and Stage IVaggressive was identified across all analyzed subgroups 
(Figure 3). In multivariate analysis, prior treatment, grade 3 tumors, triple-negative 
breast cancer, visceral metastasis, and CTC count ≥ 5 were associated with significantly 
worse survival (Table 2). Of all covariates included in the analysis, Stage IVaggressive 
disease based on CTC count was the most significant predictor (HR 2.71, 95% CI 2.35-
3.12, P<0.0001).   
 
DISCUSSION 
The recent improved breast cancer outcomes are primarily related to the 
diagnosis of disease at an early, regional stage followed by the application of 
multidisciplinary care including surgery, systemic therapy, and radiotherapy.15 Our 
current understanding of disease biology has enabled sophisticated and biologically 
driven disease stratification and staging and introduced personalized treatment 
selection that has also impacted survival and quality of life.2 MBC continues to be 
considered incurable, however, and is treated with palliative intent in spite of increased 
availability of FDA-approved therapeutic drugs designed to treat specific disease 
subtypes such as hormone receptor-positive disease.16 There is a critical need to better 
characterize MBC heterogeneity and to apply validated biomarkers for disease 
stratification and personalized, cost-effective treatment selection.17,18 Here, we 
demonstrate the validity of incorporating CTC enumeration for a new classification of 
MBC. 
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As a strong prognostic biomarker in MBC, CTCs are ideal for disease 
stratification. In this study, including the largest dataset ever reported across 18 
international centers, we tested the hypothesis that CTC count could be used to identify 
two cohorts with distinctly different outcomes, Stage IVindolent and Stage IVaggressive. We 
demonstrated that patients with the former classification had statistically significant 
longer survival compared to the Stage IVaggressive group in all the disease categories 
analyzed, including a cohort of patients with de-novo advanced disease at initial 
diagnosis. The CTC-based stratification demonstrated significant differences in overall 
survival across hormone-receptor positive, HER2-positive, and triple-negative breast 
cancer both for untreated patients and patients with prior treatment. Moreover, patients 
with visceral or bone only metastasis were also stratified accordingly. In multivariate 
analysis, CTC count was the strongest prognostic biomarker for patient survival. Thus, 
CTC count should be used to better classify the clinical and molecular heterogeneity of 
patients with MBC.   
In the last decade, several novel agents were approved by the Federal Drug 
Administration (FDA) and European Medical Agency (EMA) for the management of 
MBC with the predominance of drugs indicated for hormone receptor-positive MBC. 
Clinical trials have focused on inclusion of patients with clinically defined “endocrine-
sensitive” or “endocrine-resistant” disease with some differences in the criteria used for 
the definition, making cross-study comparisons difficult.19-24 In particular, two studies 
with appropriate long-term follow-up, PALOMA-1 and BOLERO-2, failed to demonstrate 
an improvement in overall survival of patients treated with hormone pathway-targeted 
agents in spite of a statistically significant impact on progression-free survival, raising 
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questions about the application of a combination strategy for all patients with advanced 
disease.25,26 We hypothesized that in these studies, the significant benefit of the 
investigational agents demonstrated with improved response and prolonged 
progression-free survival did not translate into an overall survival advantage because, 
irrespective of randomization, enrolled patients of both stages of the disease (indolent 
and aggressive) potentially impacted the final outcome. In fact, the aim of randomization 
in clinical trial design is to properly stratify patients into two or more groups in order to 
limit biases and to demonstrate a difference between pre-specified interventions. The 
findings in this study suggest that current clinical and molecular variables are insufficient 
to adequately stratify patients in order to demonstrate survival impact as the primary 
outcome. Patients with Stage IVaggressive MBC may receive greater relative benefit from 
novel therapies compared to Stage IVindolent. However, Stage IVaggressive disease 
constitutes only approximately 40% of cases, and survival benefits in these patients 
may be diluted over time by the lack of significant therapeutic value in the larger cohort.  
 Collectively, our study demonstrates the ability to reduce the clinical 
heterogeneity of MBC into two subgroups with different clinical outcomes, specifically 
Stage IVindolent and Stage IVaggressive as a first step to a more individualized approach to 
treatment selection and more rational drug development. This stratification can then be 
complemented by molecular analysis of CTCs and cell-free circulating tumor DNA to 
further advance understanding of molecular drivers and improve treatment 
selection.27,28   
In conclusions, we strongly believe that the large data accumulated over the 
years and the new combined analysis of the large dataset included in this study strongly 
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supports the notion that CTCs enumeration should be used for prognostic stratification 
of MBC in two defined group of patients identified as Stage IVindolent and Stage 
IVaggressive.  Therefore, we recommend that this classification being prospective utilized as 
stratification factor in future prospective clinical trials. .  
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Figure 1: Overall survival for Stage IVindolent versus Stage IVaggressive patients. 
Kaplan-Meier estimate of the duration of overall survival of patients stratified as Stage 
IVindolent (blue) and Stage IVaggressive (red) for A) the entire cohort, B) patients with de 
novo disease, C) patients with visceral metastases, D) patients with bone only 
metastases, E) and those with hormone-receptor positive, F) HER-2 positive, and G) 
triple-negative breast cancer. Censored data are indicated by tick marks.  
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 Figure 2: Cumulative hazard by disease subtype for Stage IVindolent and Stage 
IVaggressive patients. AC
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Cumulative hazard estimates for patients with hormone-receptor positive, HER-2 
positive, and triple-negative breast cancer for those with A) Stage IVindolent disease and 
B) Stage IVaggressive disease  Censored data are indicated by tick marks.  
 
Figure 3: Forest plot of overall survival, according to subgroups. HR denotes 
hazard ratio, and CI denotes confidence interval.  
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Table 1: Demographics and clinical characteristics of the patients at baseline for 
individual cohorts and combined cohort. 
Patient Characteristic Cohort 
P value 
    EPAC MDACC Combined 
Age 
Median 
[Range] 
(Years) 
60 [23-91] 53 [23-82] 57 [23-91] <0.0001 
Progressed   
1436/1944 
(73.9%) 
442/492 
(89.8%) 
1878/2436 
(77.1%) 
<0.0001 
Died 
 
929/1944 
(47.8%) 
292/492 
(59.4%) 
1221/2436 
(50.1%) 
<0.0001 
Lines of MBC 
Treatment 
Untreated 
792/1713 
(46.2%) 
220/490 
(44.9%) 
1012/2203 
(45.9%) 
0.61 
≥1 Prior 
Treatments 
921/1713 
(53.8%) 
270/490 
(55.1%) 
1191/2203 
(54.1%) 
  
Molecular 
Subtype 
HR+ 
1166/1880 
[62.0%] 
274/489 
[56.0%] 
1440/2369  
[60.8%] 
0.016 
TNBC 
240/1880 
[12.8%] 
118/489 
[24.2%] 
358/2369    
[15.1%] 
<0.0001 
HER2+ 
474/1880 
[25.2%] 
97/489 
[19.8%] 
571/2369    
[24.1%] 
0.013 
Site of 
Metastasis 
Visceral 
1318/1897 
(69.5%) 
306/492 
(62.2%) 
1624/2389 
(68.0%) 
0.002 
Bone 
1240/1897 
(65.4%) 
326/492 
(66.3%) 
1566/2389 
(65.6%) 
0.71 
CTC Count 
<5 
1033/1944 
(53.1%) 
304/492 
(61.8%) 
1337/2436 
(54.9%) 
<0.001 
≥5 
911/1944 
(46.9%) 
188/492 
(38.2%) 
1099/2436 
(45.1%) 
 
MBC: metastatic breast cancer, EPAC: European Pooled Analysis Consortium, 
MDACC: MD Anderson Cancer Center, HR+: hormone-receptor positive, TNBC: triple-
negative breast cancer, HER-2: human epidermal growth factor receptor 2 
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Table 2: Multivariate cox regression for overall survival 
Patient Characteristic HR 95% CI P value 
Age 
<45 1    
≥45 and ≤65 1.02 0.84 1.24 0.852 
≥65 1.18 0.96 1.45 0.118 
Lines of MBC 
Treatment 
Untreated 1    
≥1 Prior 
Treatments 
2.03 1.75 2.35 < 0.0001 
Grade 
1 1    
2 1.14 0.83 1.57 0.413 
3 1.46 1.06 2.00 0.02 
Molecular 
Subtype 
HR positive 1    
HER2 positive 0.89 0.74 1.01 0.176 
TNBC 1.90 1.57 2.31 < 0.0001 
Site of Metastasis 
Bone only 1    
Visceral 1.86 1.56 2.20 < 0.0001 
Type of metastatic 
onset 
Relapsed 1    
De novo 0.92 0.78 1.09 0.351 
CTC Count 
<5 1    
≥5 2.71 2.35 3.12 < 0.0001 
MBC: metastatic breast cancer, HR: hazard ratio, CI: confidence interval 
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